| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.EJPHAR.2008.03.025 |
| P698 | PubMed publication ID | 18466898 |
| P50 | author | Christian Hölscher | Q37831053 |
| Victor A. Gault | Q39188087 | ||
| P433 | issue | 1-3 | |
| P304 | page(s) | 112-117 | |
| P577 | publication date | 2008-03-29 | |
| P1433 | published in | European Journal of Pharmacology | Q1376712 |
| P1476 | title | GLP-1 agonists facilitate hippocampal LTP and reverse the impairment of LTP induced by beta-amyloid | |
| P478 | volume | 587 |
| Q44476616 | (Val(8))GLP-1-Glu-PAL: a GLP-1 agonist that improves hippocampal neurogenesis, glucose homeostasis, and β-cell function in high-fat-fed mice |
| Q48254911 | Actions of exendin-4 therapy on cognitive function and hippocampal synaptic plasticity in mice fed a high-fat diet |
| Q90725269 | Adapentpronitrile, a New Dipeptidyl Peptidase-IV Inhibitor, Ameliorates Diabetic Neuronal Injury Through Inhibiting Mitochondria-Related Oxidative Stress and Apoptosis |
| Q36538782 | Amelioration of Metabolic Syndrome-Associated Cognitive Impairments in Mice via a Reduction in Dietary Fat Content or Infusion of Non-Diabetic Plasma. |
| Q35106896 | Central proliferation and neurogenesis is impaired in type 2 diabetes and prediabetes animal models |
| Q34639384 | Chronic treatment with the GLP1 analogue liraglutide increases cell proliferation and differentiation into neurons in an AD mouse model |
| Q48479319 | Colivelin ameliorates amyloid β peptide-induced impairments in spatial memory, synaptic plasticity, and calcium homeostasis in rats |
| Q36189386 | Common variants at 12q14 and 12q24 are associated with hippocampal volume |
| Q92005722 | Effects of glucagon-like peptide 1 receptor agonists on comorbidities in older patients with diabetes mellitus |
| Q34028497 | Enhancing the GLP-1 receptor signaling pathway leads to proliferation and neuroprotection in human neuroblastoma cells |
| Q33708923 | Exendin-4 Treatment Improves LPS-Induced Depressive-Like Behavior Without Affecting Pro-Inflammatory Cytokines |
| Q41003546 | Exendin-4 protects Aβ(1-42) oligomer-induced PC12 cell apoptosis |
| Q33609502 | GIP and GLP-1, the two incretin hormones: Similarities and differences |
| Q47269433 | GLP-1 receptor regulates cell growth through regulating IDE expression level in Aβ1-42-treated PC12 cells |
| Q34167980 | GLP-1 receptor stimulation reduces amyloid-beta peptide accumulation and cytotoxicity in cellular and animal models of Alzheimer's disease. |
| Q35150153 | Genetic, psychosocial and clinical factors associated with hippocampal volume in the general population |
| Q41700809 | Glucagon-Like Peptide-1 (GLP-1) Treatment Ameliorates Cognitive Impairment by Attenuating Arc Expression in Type 2 Diabetic Rats. |
| Q28067465 | Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes |
| Q47915902 | Glucagon-like peptide-1 cleavage product GLP-1 (9-36) amide enhances hippocampal long-term synaptic plasticity in correlation with suppression of Kv4.2 expression and eEF2 phosphorylation |
| Q34362412 | Incretin mimetics as pharmacologic tools to elucidate and as a new drug strategy to treat traumatic brain injury |
| Q35768362 | Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases |
| Q48488584 | Linagliptin, a Dipeptidyl Peptidase-4 Inhibitor, Mitigates Cognitive Deficits and Pathology in the 3xTg-AD Mouse Model of Alzheimer's Disease. |
| Q90113365 | Liraglutide Protects Against Brain Amyloid-β1-42 Accumulation in Female Mice with Early Alzheimer's Disease-Like Pathology by Partially Rescuing Oxidative/Nitrosative Stress and Inflammation |
| Q38324750 | Liraglutide improves hippocampal synaptic plasticity associated with increased expression of Mash1 in ob/ob mice. |
| Q89804406 | Long-Lasting Exendin-4 Fusion Protein Improves Memory Deficits in High-Fat Diet/Streptozotocin-Induced Diabetic Mice |
| Q35568177 | Modulation of hippocampal neural plasticity by glucose-related signaling |
| Q90322035 | Neurodegeneration in type 2 diabetes: Alzheimer's as a case study |
| Q38105048 | Neurodegenerative disease and obesity: what is the role of weight loss and bariatric interventions? |
| Q36166654 | Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders |
| Q36339320 | PPG neurons of the lower brain stem and their role in brain GLP-1 receptor activation. |
| Q59812434 | Pleiotropic Effects of GLP-1 and Analogs on Cell Signaling, Metabolism, and Function |
| Q38039489 | Potential role of glucagon-like peptide-1 (GLP-1) in neuroprotection |
| Q26774021 | Potentials of incretin-based therapies in dementia and stroke in type 2 diabetes mellitus |
| Q91742866 | Recent advances in understanding the role of glucagon-like peptide 1 |
| Q37685201 | Subcutaneous liraglutide ameliorates methylglyoxal-induced Alzheimer-like tau pathology and cognitive impairment by modulating tau hyperphosphorylation and glycogen synthase kinase-3β |
| Q38036916 | Targeting synaptic dysfunction in Alzheimer's disease therapy. |
| Q37811420 | The Role of GLP-1 in Neuronal Activity and Neurodegeneration |
| Q50050282 | The diabetes drug liraglutide reverses cognitive impairment in mice and attenuates insulin receptor and synaptic pathology in a non-human primate model of Alzheimer's disease. |
| Q58610182 | The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders |
| Q26768527 | The glucagon-like peptide 1 (GLP) receptor as a therapeutic target in Parkinson's disease: mechanisms of action |
| Q33868403 | The impact of dietary energy intake on cognitive aging |
| Q37830311 | The role of G protein-coupled receptors in the pathology of Alzheimer's disease |
| Q38823805 | Therapeutic Potential of Antidiabetic Medications in the Treatment of Cognitive Dysfunction and Dementia |
Search more.